| 1 | ITF2357 regulates NF-κB signaling pathway to protect barrier integrity in retinal pigment epithelial cells. (Lim RR, Mahaling B, Tan A, Mehta M, Kaur C, Hunziker W, Kim JE, Barathi VA, Ghosh A, Chaurasia SS) FASEB J 2024 Mar 15;38(5):e23512 1 Citation |
| 1 | Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion. (Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, SCORE2 Investigator Group) Am J Ophthalmol 2022 Aug;240:330-341 10 Citations |
| 1 | Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18. (Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, SCORE2 Study Investigator Group) JAMA Ophthalmol 2022 May 01;140(5):458-464 4 Citations |
| 1 | SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion. (Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, SCORE2 Investigator Group) Graefes Arch Clin Exp Ophthalmol 2022 May;260(5):1491-1500 4 Citations |
| 1 | Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial. (Maguire MG, Liu D, Bressler SB, Friedman SM, Melia M, Stockdale CR, Glassman AR, Sun JK, DRCR Retina Network) JAMA Ophthalmol 2021 Dec 01;139(12):1266-1273 18 Citations |
| 1 | A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE). (Kim JE, Glassman AR, Josic K, Melia M, Aiello LP, Baker C, Eells JT, Jampol LM, Kern TS, Marcus D, Salehi-Had H, Shah SN, Martin DF, Stockdale CR, Sun JK, DRCR Retina Network) Ophthalmol Retina 2022 Apr;6(4):298-307 26 Citations |
| 1 | NOD-like Receptors in the Eye: Uncovering Its Role in Diabetic Retinopathy. (Lim RR, Wieser ME, Ganga RR, Barathi VA, Lakshminarayanan R, Mohan RR, Hainsworth DP, Chaurasia SS) Int J Mol Sci 2020 Jan 30;21(3) 46 Citations |
| 1 | Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. (Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW, SCORE2 Investigator Group) JAMA Ophthalmol 2019 Mar 01;137(3):281-287 15 Citations |
| 1 | Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. (Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC, Diabetic Retinopathy Clinical Research Network) Ophthalmology 2018 Jul;125(7):1054-1063 33 Citations |
| 1 | Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. (Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Altaweel M, Berinstein DM, SCORE2 Investigator Group) JAMA Ophthalmol 2018 Apr 01;136(4):337-345 34 Citations |
| 1 | SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion. (Scott IU, Figueroa MJ, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC, SCORE2 Investigator Group) Am J Ophthalmol 2017 Dec;184:147-156 8 Citations |
| 1 | Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. (Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, King J, Antoszyk AN, Peters MA, Tolentino M, SCORE2 Investigator Group) JAMA Ophthalmol 2017 Jun 01;135(6):639-649 43 Citations |
| 1 | Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. (Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J, SCORE2 Investigator Group) JAMA 2017 May 23;317(20):2072-2087 190 Citations |
| 1 | SCORE2 Report 2: Study Design and Baseline Characteristics. (Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M, Dugel PU, SCORE2 Investigator Group) Ophthalmology 2017 Feb;124(2):245-256 28 Citations |
| 1 | Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. (Jampol LM, Glassman AR, Bressler NM, Wells JA, Ayala AR, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2016 Dec 01;134(12) 51 Citations |
| 1 | Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. (Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW, Diabetic Retinopathy Clinical Research Network) Ophthalmology 2016 Jun;123(6):1351-9 778 Citations |
| 1 | Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. (Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2016 Feb;134(2):127-34 61 Citations |
| 1 | Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15. (Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC, SCORE Study Investigator Group) JAMA Ophthalmol 2015 Sep;133(9):1022-9 40 Citations |
| 1 | En Face Optical Coherence Tomography of Outer Retinal Discontinuity and Fan-Shaped Serous Macular Detachment in Diabetic Macular Edema. (Abozaid MA, Scoles D, Goldberg M, Carroll J, Han DP) JAMA Ophthalmol 2015 Aug;133(8):961-3 2 Citations |
| 1 | Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. (Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators) JAMA Ophthalmol 2015 May;133(5):589-97 70 Citations |
| 1 | Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW) N Engl J Med 2015 Mar 26;372(13):1193-203 1333 Citations |
| 1 | Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye. (Karth PA, Chang A, Wirostko W) Graefes Arch Clin Exp Ophthalmol 2014 Feb;252(2):207-11 8 Citations |
| 1 | Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. (Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2013 Aug;131(8):1033-40 100 Citations |
| 2 | Subclinical macular findings in infants screened for retinopathy of prematurity with spectral-domain optical coherence tomography. (Dubis AM, Subramaniam CD, Godara P, Carroll J, Costakos DM) Ophthalmology 2013 Aug;120(8):1665-71 79 Citations |
| 1 | Adaptive optics and spectral- domain optical coherence tomography of human photoreceptor structure after short-duration [corrected] pascal macular grid and panretinal laser photocoagulation. (Han DP, Croskrey JA, Dubis AM, Schroeder B, Rha J, Carroll J) Arch Ophthalmol 2012 Apr;130(4):518-21 14 Citations |
| 1 | Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. (Loftus JV, Sultan MB, Pleil AM, Macugen 1013 Study Group) Invest Ophthalmol Vis Sci 2011 Sep 29;52(10):7498-505 31 Citations |
| 1 | Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. (Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD, Diabetic Retinopathy Clinical Research Network) Invest Ophthalmol Vis Sci 2011 Aug 03;52(9):6168-73 33 Citations |
| 1 | A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. (Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, Macugen 1013 Study Group) Ophthalmology 2011 Jun;118(6):1107-18 146 Citations |
| 1 | Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10. (Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Hartnett ME, Cohen G, Standard Care versus COrticosteroid for REtinal Vein Occlusion Study Investigator Group) Ophthalmology 2011 Feb;118(2):345-52 78 Citations |
| 1 | Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK) Ophthalmology 2010 Jun;117(6):1064-1077.e35 1277 Citations |
| 1 | A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. (Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group) Arch Ophthalmol 2009 Sep;127(9):1101-14 471 Citations |
| 1 | SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. (Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN, SCORE Study Investigator Group) Am J Ophthalmol 2009 Nov;148(5):725-732.e7 43 Citations |
| 1 | Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. (Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM, Pegaptanib in Central Retinal Vein Occlusion Study Group) Arch Ophthalmol 2009 Apr;127(4):374-80 86 Citations |
| 1 | SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. (Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M, SCORE Study Investigator Group) Ophthalmology 2009 Mar;116(3):504-12 111 Citations |
| 1 | Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. (Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H, Diabetic Retinopathy Clinical Research Network) Ophthalmology 2008 Aug;115(8):1366-71, 1371.e1 145 Citations |
| 1 | A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. (Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD, Macugen Diabetic Retinopathy Study Group) Ophthalmology 2005 Oct;112(10):1747-57 558 Citations |
